Boehringer Ingelheim gets CDSCO nod for Jardiance to treat for new heart failure indication
Jardiance is the top selling drug of BI in India, used in treatment of type-2 diabetes and for the treatment of heart failure with reduced ejection fraction (HFrEF). The latest approval by CDSCO is for the treatment of heart failure with preserved ejection fraction (HFpEF). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 19, 2022 Category: Pharmaceuticals Source Type: news

Positive Topline Results for Dapagliflozin in HFpEF: DELIVER Positive Topline Results for Dapagliflozin in HFpEF: DELIVER
AstraZeneca says regulatory submissions will be forthcoming, potentially bringing a second SGLT2 inhibitor in this space, after empagliflozin.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 5, 2022 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news

Empagliflozin Rapidly Improves Acute Heart Failure Symptoms Empagliflozin Rapidly Improves Acute Heart Failure Symptoms
Empagliflozin showed symptomatic benefits in patients hospitalized for acute heart failure after 2 weeks in a secondary analysis from the EMPULSE trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

ACC: Empagliflozin Offers Clinical Benefit in Heart Failure
WEDNESDAY, April 13, 2022 -- For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2022 Category: Pharmaceuticals Source Type: news

Himachal Pradesh high court restrains DRL from selling BI's diabetic drug Jardiance
The drugmaker said it is reviewing legal options including filing an appeal against the court order. Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 31, 2022 Category: Pharmaceuticals Source Type: news

Empagliflozin Scores Topline Win in EMPA-KIDNEY Trial Empagliflozin Scores Topline Win in EMPA-KIDNEY Trial
Researchers stopped the 6600-patient EMPA-KIDNEY trial sooner than expected because it positively met prespecified efficacy criteria in a trial of patients with CKD with or without diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 17, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Mar 4 2022 This Week in Cardiology Mar 4 2022 This Week in Cardiology
An update to CardioMEMs post, ARBs and cancer, troponins, empagliflozin, and low-value care are the topics discussed by John Mandrola, MD, in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 4, 2022 Category: Cardiology Tags: Cardiology Commentary Source Type: news

FDA Expands Approval of Jardiance for Patients With Heart Failure
MONDAY, Feb. 28, 2022 -- Approval for Jardiance (empagliflozin) has been expanded to reduce the risk for cardiovascular death and hospitalization for heart failure in adults, the U.S. Food and Drug Administration announced Thursday. Jardiance... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2022 Category: Pharmaceuticals Source Type: news

US FDA Approves Jardiance (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 25, 2022 Category: Drugs & Pharmacology Source Type: news

FDA Okays Empagliflozin for HF Regardless of Ejection Fraction FDA Okays Empagliflozin for HF Regardless of Ejection Fraction
The expanded indication for the SGLT2 inhibitor empagliflozin (Jardiance) now includes heart failure with mid-range or preserved left-ventricular ejection fraction — essentially all heart failure.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 24, 2022 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA approves treatment for wider range of patients with heart failure
Today, the U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes. (Source: World Pharma News)
Source: World Pharma News - February 24, 2022 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Semaglutide + metformin not cost effective vs empagliflozin + metformin for T2DM in Denmark
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2021 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim's diabetes pill Jardiance gets CDSCO nod for use against heart failure
German drug maker Boehringer Ingelheim has won approval from the Indian drug regulator to market its top-selling type-2 diabetes medication Jardiance (empagliflozin) in India, for additional indication to reduce the risk of heart failure in adults. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 22, 2021 Category: Pharmaceuticals Source Type: news

Empagliflozin Wins in Tough Stabilized Acute-HF Setting Empagliflozin Wins in Tough Stabilized Acute-HF Setting
Early in-hospital initiation of SGLT2 inhibitors ' should be considered the new standard of care ' in most patients with heart failure regardless of their ejection fraction, says an expert observer.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 16, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Advanced CKD Doesn't Derail Empagliflozin in EMPEROR-Preserved Advanced CKD Doesn't Derail Empagliflozin in EMPEROR-Preserved
A prespecified data analysis from EMPEROR-Preserved in patients with HFpEF showed consistent efficacy and safety results for empagliflozin regardless of chronic kidney disease status.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 12, 2021 Category: Cardiology Tags: Pathology & Lab Medicine News Source Type: news